Cerevel Therapeutics to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021
July 22 2021 - 7:00AM
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to
unraveling the mysteries of the brain
to treat neuroscience diseases, today announced it
will report second quarter 2021 financial results and provide a
pipeline update on Wednesday, August 11, 2021, before the U.S.
financial markets open.
Management will host a conference call to
discuss second quarter 2021 financial results and recent business
and pipeline updates on Wednesday, August 11, 2021 at 8:00 a.m.
EDT. To access the call, please dial 833-665-0655 (domestic) or
702-495-1044 (international) and refer to conference ID
8947263.
A live webcast of the call, along with
supporting slides, will be available on the investors section of
Cerevel’s website at investors.cerevel.com. Following the live
webcast, an archived version of the call will be available on the
website.
About Cerevel
TherapeuticsCerevel Therapeutics is dedicated to
unraveling the mysteries of the brain to treat neuroscience
diseases. The company is tackling diseases with a targeted approach
to neuroscience that combines expertise in neurocircuitry with a
focus on receptor selectivity. Cerevel Therapeutics has a
diversified pipeline comprising five clinical-stage investigational
therapies and several pre-clinical compounds with the potential to
treat a range of neuroscience diseases, including Parkinson’s,
epilepsy, schizophrenia, and substance use disorder. Headquartered
in Cambridge, Mass., Cerevel Therapeutics is advancing its current
research and development programs while exploring new modalities
through internal research efforts, external collaborations, or
potential acquisitions. For more information,
visit www.cerevel.com.
Special Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements that are based on management’s beliefs and assumptions
and on information currently available to management. In some
cases, you can identify forward-looking statements by the following
words: “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. Although we believe that we
have a reasonable basis for each forward-looking statement
contained in this press release, we caution you that these
statements are based on a combination of facts and factors
currently known by us and our projections of the future, about
which we cannot be certain. Forward-looking statements in this
press release include, but are not limited to, statements about the
timing of reporting of our second quarter 2021 financial results
and the potential attributes and benefits of our product
candidates. We cannot assure you that the forward-looking
statements in this press release will prove to be accurate.
Furthermore, if the forward-looking statements prove to be
inaccurate, the inaccuracy may be material. Actual performance and
results may differ materially from those projected or suggested in
the forward-looking statements due to various risks and
uncertainties, including, among others: clinical trial results may
not be favorable; uncertainties inherent in the product development
process (including with respect to the timing of results and
whether such results will be predictive of future results); the
impact of COVID-19 on the timing, progress and results of ongoing
or planned clinical trials; other impacts of COVID-19, including
operational disruptions or delays or to our ability to raise
additional capital; whether and when, if at all, our product
candidates will receive approval from the FDA or other regulatory
authorities, and for which, if any, indications; competition from
other biotechnology companies; uncertainties regarding intellectual
property protection; and other risks identified in our SEC filings,
including those under the heading “Risk Factors” in our Form S-1
Registration Statement filed with the SEC on June 29, 2021 and our
subsequent SEC filings. In light of the significant uncertainties
in these forward-looking statements, you should not regard these
statements as a representation or warranty by us or any other
person that we will achieve our objectives and plans in any
specified time frame, or at all. The forward-looking statements in
this press release represent our views as of the date of this press
release. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update
these forward-looking statements at some point in the future, we
have no current intention of doing so except to the extent required
by applicable law. You should, therefore, not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release.
Media Contact:Kate
ContrerasReal Chemistry kcontreras@realchemistry.com
Investor Contact:Matthew
CalistriCerevel Therapeuticsmatthew.calistri@cerevel.com
Cerevel Therapeutics (NASDAQ:CERE)
Historical Stock Chart
From Apr 2024 to May 2024
Cerevel Therapeutics (NASDAQ:CERE)
Historical Stock Chart
From May 2023 to May 2024